Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IB Trial of Induction Nivolumab or Nivolumab/Ipilimumab Prior to Concurrent Chemoradiation Plus Nivolumab in Patients With Operable Stage II/III Esophageal/ Gastroesophageal Junction Cancer

Trial Profile

Phase IB Trial of Induction Nivolumab or Nivolumab/Ipilimumab Prior to Concurrent Chemoradiation Plus Nivolumab in Patients With Operable Stage II/III Esophageal/ Gastroesophageal Junction Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Jan 2019

At a glance

  • Drugs Nivolumab (Primary) ; Relatlimab (Primary) ; Carboplatin; Paclitaxel
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Jan 2019 Results (n=16) presented at the 2019 Gastrointestinal Cancers Symposium
    • 08 Jan 2019 Planned End Date changed from 1 Feb 2022 to 1 Feb 2025.
    • 08 Jan 2019 Planned primary completion date changed from 1 Feb 2019 to 1 Feb 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top